vorinostat has been researched along with Uveal Neoplasms in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Uveal Neoplasms: Tumors or cancer of the UVEA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landreville, S | 1 |
| Agapova, OA | 1 |
| Matatall, KA | 1 |
| Kneass, ZT | 1 |
| Onken, MD | 1 |
| Lee, RS | 1 |
| Bowcock, AM | 1 |
| Harbour, JW | 1 |
1 other study available for vorinostat and Uveal Neoplasms
| Article | Year |
|---|---|
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemorad | 2012 |